LPL Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

LPL Financial’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-33,493	Closed	-$807K	–	4748
2023 Q1	$807K	Sell	33,493 -14,290	-30%	-$179K	﹤0.01%	2920
2022 Q4	$505K	Buy	47,783 +17,900	+60%	+$144K	﹤0.01%	3235
2022 Q3	$134K	Buy	29,883 +21	+0.1%	+$96	﹤0.01%	4050
2022 Q2	$119K	Sell	29,862 -1,567	-5%	-$7.43K	﹤0.01%	4094
2022 Q1	$230K	Buy	31,429 +1,177	+4%	+$7.04K	﹤0.01%	3758
2021 Q4	$170K	Sell	30,252 -3,500	-10%	-$22.2K	﹤0.01%	4026
2021 Q3	$216K	Buy	+33,752	New	+$217K	﹤0.01%	3916

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

LPL Financial's PRVB Position: Q2 2023 in Review

LPL Financial sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 33,493 shares — an estimated $807K sold.

LPL Financial first reported a position in PRVB in Q3 2021 and held it in 7 quarters. The position peaked at $807K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

LPL Financial reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
LPL Financial sold 33,493 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $807K.
LPL Financial first reported a position in Provention Bio, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
LPL Financial's Provention Bio, Inc. Common Stock position peaked at $807K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on LPL Financial's 13F filing for Q2 2023, filed 31 Jul 2023.